Minds + Machines Group Limited

Minds + Machines makes strong start to 2019 as recurring revenues climb

Gross revenues rose by 5% to US$15.1mn in 2018, with recurring revenues 97% higher at US$9.4mln

internet user
China is seeing good growth in registrations

Minds & Machines PLC (LON:MMX) has seen an ‘exceptionally strong’ start to the current year while recurring revenues now account for the majority of income.

The registry owns a raft of internet addresses including .law, .luxe and .xxx.

Gross revenues rose by 5% to US$15.1mn in 2018, with recurring revenues 97% higher at  US$9.4mln, which surpassed overheads for the first time said MMX.

Losses though soared to US$12.7mln as the company cleared out loss-making contracts, bad debts and wrote-down assets.

In 2019 so far, domain registrations are up to 1.87mln from 1.81mln at the year-end.

First quarter billings rose by 246% due to a combination of the first time ICM contribution and a significant increase in billings from China, helped by .law registrations.

Toby Hall, chief executive, said: “ 2019 has started exceptionally well.

"Q1 sales are significantly ahead of the same period last year resulting from a combination of the first time contribution from ICM, healthy trading in China and steady growth in sales from the European and US teams.

“We likewise look forward to the benefits of certain underlying contract renegotiations beginning to feed through into the business in H2 and the subsequent period; the business is now well positioned for ongoing growth."

Quick facts: Minds + Machines Group Limited

Price: £0.06

Market: AIM
Market Cap: £53.15 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Minds + Machines Group Limited named herein, including the promotion by the Company of Minds + Machines Group Limited in any Content on the...



Investor Update: Shield Therapeutics targets $1bn US market after FDA...

Top stories from the Proactive Investors UK newsroom. Shield Therapeutics (LON:STX) has been given approval by the US Food and Drug Administration to sell its lead product Feraccru as a treatment for iron deficiency in adults. The US prescription market for iron replacement therapy is...

4 weeks ago

2 min read